West Pharmaceutical Services (WST) Non-Current Debt (2016 - 2025)
West Pharmaceutical Services' Non-Current Debt history spans 17 years, with the latest figure at $202.8 million for Q4 2025.
- For Q4 2025, Non-Current Debt changed 0.1% year-over-year to $202.8 million; the TTM value through Dec 2025 reached $202.8 million, changed 0.1%, while the annual FY2025 figure was $202.8 million, 0.1% changed from the prior year.
- Non-Current Debt for Q4 2025 was $202.8 million at West Pharmaceutical Services, roughly flat from $202.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $252.3 million in Q1 2021 and bottomed at $72.8 million in Q4 2023.
- The 5-year median for Non-Current Debt is $204.2 million (2023), against an average of $187.5 million.
- The largest annual shift saw Non-Current Debt tumbled 64.78% in 2023 before it skyrocketed 178.3% in 2024.
- A 5-year view of Non-Current Debt shows it stood at $208.8 million in 2021, then decreased by 1.01% to $206.7 million in 2022, then crashed by 64.78% to $72.8 million in 2023, then surged by 178.3% to $202.6 million in 2024, then increased by 0.1% to $202.8 million in 2025.
- Per Business Quant, the three most recent readings for WST's Non-Current Debt are $202.8 million (Q4 2025), $202.7 million (Q3 2025), and $202.6 million (Q2 2025).